{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T18:13:49Z","timestamp":1770747229452,"version":"3.49.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","award":["2015\/19\/B\/NZ2\/02453"],"award-info":[{"award-number":["2015\/19\/B\/NZ2\/02453"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","award":["2021\/41\/B\/NZ3\/03803"],"award-info":[{"award-number":["2021\/41\/B\/NZ3\/03803"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005632","name":"Narodowe Centrum Bada\u0144 i Rozwoju","doi-asserted-by":"publisher","award":["ERA-NET-E-RARE-3\/III\/TreatPolyQ\/08\/2018"],"award-info":[{"award-number":["ERA-NET-E-RARE-3\/III\/TreatPolyQ\/08\/2018"]}],"id":[{"id":"10.13039\/501100005632","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Biol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The majority of genes in the human genome is present in two copies but the expression levels of both alleles is not equal. Allelic imbalance is an aspect of gene expression relevant not only in the context of genetic variation, but also to understand the pathophysiology of genes implicated in genetic disorders, in particular, dominant genetic diseases where patients possess one normal and one mutant allele. Polyglutamine (polyQ) diseases are caused by the expansion of CAG trinucleotide tracts within specific genes. Spinocerebellar ataxia type 3 (SCA3) and Huntington\u2019s disease (HD) patients harbor one normal and one mutant allele that differ in the length of CAG tracts. However, assessing the expression level of individual alleles is challenging due to the presence of abundant CAG repeats in the human transcriptome, which make difficult the design of allele-specific methods, as well as of therapeutic strategies to selectively engage CAG sequences in mutant transcripts.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>To precisely quantify expression in an allele-specific manner, we used SNP variants that are linked to either normal or CAG expanded alleles of the ataxin-3 (<jats:italic>ATXN3<\/jats:italic>) and huntingtin (<jats:italic>HTT<\/jats:italic>) genes in selected patient-derived cell lines. We applied a SNP-based quantitative droplet digital PCR (ddPCR) protocol for precise determination of the levels of transcripts in cellular and mouse models. For HD, we showed that the process of cell differentiation can affect the ratio between endogenous alleles of <jats:italic>HTT<\/jats:italic> mRNA. Additionally, we reported changes in the absolute number of the <jats:italic>ATXN3<\/jats:italic> and <jats:italic>HTT<\/jats:italic> transcripts per cell during neuronal differentiation. We also implemented our assay to reliably monitor, in an allele-specific manner, the silencing efficiency of mRNA-targeting therapeutic approaches for HD. Finally, using the humanized Hu128\/21 HD mouse model, we showed that the ratio of normal and mutant <jats:italic>HTT<\/jats:italic> transgene expression in brain slightly changes with the age of mice.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Using allele-specific ddPCR assays, we observed differences in allele expression levels in the context of SCA3 and HD. Our allele-selective approach is a reliable and quantitative method to analyze low abundant transcripts and is performed with high accuracy and reproducibility. Therefore, the use of this approach can significantly improve understanding of allele-related mechanisms, e.g., related with mRNA processing that may be affected in polyQ diseases.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12915-023-01515-3","type":"journal-article","created":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T21:02:46Z","timestamp":1675285366000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Allele-specific quantitation of ATXN3 and HTT transcripts in polyQ disease models"],"prefix":"10.1186","volume":"21","author":[{"given":"Pawe\u0142","family":"Joachimiak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Ciesio\u0142ka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilia","family":"Koz\u0142owska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pawe\u0142 M.","family":"\u015awito\u0144ski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grzegorz","family":"Figura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agata","family":"Cio\u0142ak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gra\u017cyna","family":"Adamek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"Surdyka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u017baneta","family":"Kalinowska-Po\u015bka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maciej","family":"Figiel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas S.","family":"Caron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael R.","family":"Hayden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7829-1926","authenticated-orcid":false,"given":"Agnieszka","family":"Fiszer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,2,1]]},"reference":[{"key":"1515_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev-pathmechdis-012418-012857","volume":"14","author":"AP Lieberman","year":"2019","unstructured":"Lieberman AP, Shakkottai VG, Albin RL. Polyglutamine repeats in neurodegenerative diseases. Annu Rev Pathol Mech Dis. 2019;14:1\u201327.","journal-title":"Annu Rev Pathol Mech Dis"},{"key":"1515_CR2","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.conb.2021.07.001","volume":"72","author":"EL Bunting","year":"2022","unstructured":"Bunting EL, Hamilton J, Tabrizi SJ. Polyglutamine diseases. Curr Opin Neurobiol. 2022;72:39\u201347.","journal-title":"Curr Opin Neurobiol"},{"key":"1515_CR3","first-page":"143","volume-title":"Handbook of Clinical Neurology","author":"CA Stoyas","year":"2018","unstructured":"Stoyas CA, La Spada AR. The CAG\u2013polyglutamine repeat diseases: a clinical, molecular, genetic, and pathophysiologic nosology. In:  Handbook of Clinical Neurology: Elsevier; 2018. p. 143\u201370."},{"key":"1515_CR4","doi-asserted-by":"publisher","first-page":"104635","DOI":"10.1016\/j.nbd.2019.104635","volume":"134","author":"HS McLoughlin","year":"2020","unstructured":"McLoughlin HS, Moore LR, Paulson HL. Pathogenesis of SCA3 and implications for other polyglutamine diseases. Neurobiol Dis. 2020;134:104635.","journal-title":"Neurobiol Dis"},{"key":"1515_CR5","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/s41582-020-0389-4","volume":"16","author":"SJ Tabrizi","year":"2020","unstructured":"Tabrizi SJ, Flower MD, Ross CA, Wild EJ. Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities. Nat Rev Neurol. 2020;16:529\u201346.","journal-title":"Nat Rev Neurol"},{"key":"1515_CR6","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1016\/j.bpj.2018.02.037","volume":"114","author":"T Yushchenko","year":"2018","unstructured":"Yushchenko T, Deuerling E, Hauser K. Insights into the aggregation mechanism of PolyQ proteins with different glutamine repeat lengths. Biophys J. 2018;114:1847\u201357.","journal-title":"Biophys J"},{"key":"1515_CR7","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1093\/protein\/gzp033","volume":"22","author":"HM Saunders","year":"2009","unstructured":"Saunders HM, Bottomley SP. Multi-domain misfolding: understanding the aggregation pathway of polyglutamine proteins. Protein Eng Design Select. 2009;22:447\u201351.","journal-title":"Protein Eng Design Select"},{"key":"1515_CR8","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1007\/s13311-019-00798-1","volume":"16","author":"JD Da Silva","year":"2019","unstructured":"Da Silva JD, Teixeira-Castro A, Maciel P. From pathogenesis to novel therapeutics for spinocerebellar ataxia type 3: evading potholes on the way to translation. Neurotherapeutics. 2019;16:1009\u201331.","journal-title":"Neurotherapeutics"},{"key":"1515_CR9","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/jnc.14541","volume":"148","author":"CA Matos","year":"2019","unstructured":"Matos CA, de Almeida LP, N\u00f3brega C. Machado\u2013Joseph disease\/spinocerebellar ataxia type 3: lessons from disease pathogenesis and clues into therapy. J Neurochem. 2019;148:8\u201328.","journal-title":"J Neurochem"},{"key":"1515_CR10","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1038\/cddis.2013.276","volume":"4","author":"R Nalavade","year":"2013","unstructured":"Nalavade R, Griesche N, Ryan DP, Hildebrand S, Krau\u00df S. Mechanisms of RNA-induced toxicity in CAG repeat disorders. Cell Death Dis. 2013;4:752.","journal-title":"Cell Death Dis"},{"key":"1515_CR11","doi-asserted-by":"publisher","first-page":"431","DOI":"10.3389\/fncel.2014.00431","volume":"8","author":"HYE Chan","year":"2014","unstructured":"Chan HYE. RNA-mediated pathogenic mechanisms in polyglutamine diseases and amyotrophic lateral sclerosis. Front Cellular Neurosci. 2014;8:431.","journal-title":"Front Cellular Neurosci"},{"key":"1515_CR12","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1111\/bpa.12427","volume":"26","author":"E Mart\u00ed","year":"2016","unstructured":"Mart\u00ed E. RNA toxicity induced by expanded CAG repeats in Huntington\u2019s disease. Brain Pathol. 2016;26:779\u201386.","journal-title":"Brain Pathol"},{"key":"1515_CR13","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s00109-013-1016-2","volume":"91","author":"A Fiszer","year":"2013","unstructured":"Fiszer A, Krzyzosiak WJ. RNA toxicity in polyglutamine disorders: concepts, models, and progress of research. J Mol Med. 2013;91:683\u201391.","journal-title":"J Mol Med"},{"key":"1515_CR14","doi-asserted-by":"publisher","first-page":"4409","DOI":"10.1093\/brain\/awac241","volume":"145","author":"S Fienko","year":"2022","unstructured":"Fienko S, Landles C, Sathasivam K, McAteer SJ, Milton RE, Osborne GF, et al. Alternative processing of human HTT mRNA with implications for Huntington\u2019s disease therapeutics. Brain. 2022;145:4409\u201324.","journal-title":"Brain"},{"key":"1515_CR15","first-page":"9050","volume":"44","author":"M Jazurek","year":"2016","unstructured":"Jazurek M, Ciesiolka A, Starega-Roslan J, Bilinska K, Krzyzosiak WJ. Identifying proteins that bind to specific RNAs - focus on simple repeat expansion diseases. Nucleic Acids Res. 2016;44:9050\u201370.","journal-title":"Nucleic Acids Res"},{"key":"1515_CR16","doi-asserted-by":"crossref","unstructured":"An Y, Chen ZS, Yin H, Chan E, Chi J, Ngo K. Molecular insights into the interaction of CAG trinucleotide RNA repeats with nucleolin and its implication in polyglutamine diseases. 2022;50:7655\u201368.","DOI":"10.1093\/nar\/gkac532"},{"key":"1515_CR17","doi-asserted-by":"publisher","first-page":"fcac248","DOI":"10.1093\/braincomms\/fcac248","volume":"4","author":"S Ly","year":"2022","unstructured":"Ly S, Didiot M-C, Ferguson CM, Coles AH, Miller R, Chase K, et al. Mutant huntingtin messenger RNA forms neuronal nuclear clusters in rodent and human brains. Brain Commun. 2022;4:fcac248.","journal-title":"Brain Commun"},{"key":"1515_CR18","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/nature22386","volume":"546","author":"A Jain","year":"2017","unstructured":"Jain A, Vale RD. RNA phase transitions in repeat expansion disorders. Nature. 2017;546:243\u20137.","journal-title":"Nature"},{"key":"1515_CR19","doi-asserted-by":"publisher","first-page":"677","DOI":"10.3390\/cells11040677","volume":"11","author":"P Joachimiak","year":"2022","unstructured":"Joachimiak P, Ciesio\u0142ka A, Figura G, Fiszer A. Implications of Poly(A) tail processing in repeat expansion diseases. Cells. 2022;11:677.","journal-title":"Cells"},{"key":"1515_CR20","doi-asserted-by":"publisher","first-page":"6787","DOI":"10.1093\/nar\/gku385","volume":"42","author":"A Fiszer","year":"2014","unstructured":"Fiszer A, Krzyzosiak WJ. Oligonucleotide-based strategies to combat polyglutamine diseases. Nucleic Acids Res. 2014;42:6787\u2013810.","journal-title":"Nucleic Acids Res"},{"key":"1515_CR21","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/nature11405","volume":"489","author":"MJ Hawrylycz","year":"2012","unstructured":"Hawrylycz MJ, Lein ES, Guillozet-Bongaarts AL, Shen EH, Ng L, Miller JA, et al. An anatomically comprehensive atlas of the adult human brain transcriptome. Nature. 2012;489:391\u20139.","journal-title":"Nature"},{"key":"1515_CR22","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/j.omtn.2020.01.012","volume":"19","author":"BR Anderson","year":"2020","unstructured":"Anderson BR, Jensen ML, Hagedorn PH, Little SC, Olson RE, Ammar R, et al. Allele-selective knockdown of MYH7 using antisense oligonucleotides. Mol Ther - Nucleic Acids. 2020;19:1290\u20138.","journal-title":"Mol Ther - Nucleic Acids"},{"key":"1515_CR23","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1089\/nat.2013.0427","volume":"23","author":"DW Dodd","year":"2013","unstructured":"Dodd DW, Gagnon KT, Corey DR. Digital quantitation of potential therapeutic target RNAs. Nucleic Acid Ther. 2013;23:188\u201394.","journal-title":"Nucleic Acid Ther"},{"key":"1515_CR24","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.omtn.2019.07.004","volume":"17","author":"E Kourkouta","year":"2019","unstructured":"Kourkouta E, Weij R, Gonz\u00e1lez-Barriga A, Mulder M, Verheul R, Bosgra S, et al. Suppression of mutant protein expression in SCA3 and SCA1 mice using a CAG repeat-targeting antisense oligonucleotide. Mol Ther - Nucleic Acids. 2019;17:601\u201314.","journal-title":"Mol Ther - Nucleic Acids"},{"key":"1515_CR25","doi-asserted-by":"publisher","first-page":"5885","DOI":"10.1038\/s41598-018-24156-x","volume":"8","author":"M Wojciechowska","year":"2018","unstructured":"Wojciechowska M, Sobczak K, Kozlowski P, Sedehizadeh S, Wojtkowiak-Szlachcic A, Czubak K, et al. Quantitative methods to monitor RNA biomarkers in myotonic dystrophy. Sci Rep. 2018;8:5885.","journal-title":"Sci Rep"},{"key":"1515_CR26","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1074\/jbc.RA118.005801","volume":"294","author":"D Weish\u00e4upl","year":"2019","unstructured":"Weish\u00e4upl D, Schneider J, Pinheiro BP, Ruess C, Dold SM, von Zweydorf F, et al. Physiological and pathophysiological characteristics of ataxin-3 isoforms. J Biol Chem. 2019;294:644\u201361.","journal-title":"J Biol Chem"},{"key":"1515_CR27","doi-asserted-by":"publisher","unstructured":"Melo ARV, Raposo M, Ventura M, Martins S, Pav\u00e3o S, Alonso I, et al. Genetic Variation in ATXN3 (Ataxin-3) 3\u2032UTR: insights into the downstream regulatory elements of the causative gene of Machado-Joseph disease\/spinocerebellar ataxia type 3. Cerebellum. 2022. https:\/\/doi.org\/10.1007\/s12311-021-01358-0.","DOI":"10.1007\/s12311-021-01358-0"},{"key":"1515_CR28","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1007\/s00018-020-03596-7","volume":"78","author":"A Ciesiolka","year":"2021","unstructured":"Ciesiolka A, Stroynowska-Czerwinska A, Joachimiak P, Ciolak A, Kozlowska E, Michalak M, et al. Artificial miRNAs targeting CAG repeat expansion in ORFs cause rapid deadenylation and translation inhibition of mutant transcripts. Cell Mol Life Sci. 2021;78:1577\u201396.","journal-title":"Cell Mol Life Sci"},{"key":"1515_CR29","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1016\/j.ajhg.2019.10.011","volume":"105","author":"C Kay","year":"2019","unstructured":"Kay C, Collins JA, Caron NS, de Agostinho LA, Findlay-Black H, Casal L, et al. A comprehensive haplotype-targeting strategy for allele-specific HTT suppression in Huntington disease. Am J Hum Genet. 2019;105:1112\u201325.","journal-title":"Am J Hum Genet"},{"key":"1515_CR30","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/j.cub.2009.03.030","volume":"19","author":"EL Pfister","year":"2009","unstructured":"Pfister EL, Kennington L, Straubhaar J, Wagh S, Liu W, DiFiglia M, et al. Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington\u2019s disease patients. Curr Biol. 2009;19:774\u20138.","journal-title":"Curr Biol"},{"key":"1515_CR31","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.3390\/ijms21051854","volume":"21","author":"M Dabrowska","year":"2020","unstructured":"Dabrowska M, Ciolak A, Kozlowska E, Fiszer A, Olejniczak M. Generation of new isogenic models of Huntington\u2019s disease using CRISPR-Cas9 technology. Int J Mol Sci. 2020;21:1854.","journal-title":"Int J Mol Sci"},{"key":"1515_CR32","doi-asserted-by":"publisher","first-page":"10426","DOI":"10.1093\/nar\/gkt825","volume":"41","author":"A Fiszer","year":"2013","unstructured":"Fiszer A, Olejniczak M, Galka-Marciniak P, Mykowska A, Krzyzosiak WJ. Self-duplexing CUG repeats selectively inhibit mutant huntingtin expression. Nucleic Acids Res. 2013;41:10426\u201337.","journal-title":"Nucleic Acids Res"},{"key":"1515_CR33","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.neures.2005.06.021","volume":"53","author":"YL Wang","year":"2005","unstructured":"Wang YL, Liu W, Wada E, Murata M, Wada K, Kanazawa I. Clinico-pathological rescue of a model mouse of Huntington\u2019s disease by siRNA. Neurosci Res. 2005;53:241\u20139.","journal-title":"Neurosci Res"},{"key":"1515_CR34","first-page":"1115","volume":"26","author":"AL Southwell","year":"2017","unstructured":"Southwell AL, Skotte NH, Villanueva EB, \u00d8stergaard ME, Gu X, Kordasiewicz HB, et al. A novel humanized mouse model of Huntington disease for preclinical development of therapeutics targeting mutant huntingtin alleles. Hum Mol Genet. 2017;26:1115\u201332.","journal-title":"Hum Mol Genet"},{"key":"1515_CR35","doi-asserted-by":"publisher","first-page":"487","DOI":"10.3390\/toxins13070487","volume":"13","author":"A Heinz","year":"2021","unstructured":"Heinz A, Nabariya DK, Krauss S. Huntingtin and its role in mechanisms of RNA-mediated toxicity. Toxins. 2021;13:487.","journal-title":"Toxins"},{"key":"1515_CR36","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1093\/nar\/gkr729","volume":"40","author":"WJ Krzyzosiak","year":"2012","unstructured":"Krzyzosiak WJ, Sobczak K, Wojciechowska M, Fiszer A, Mykowska A, Kozlowski P. Triplet repeat RNA structure and its role as pathogenic agent and therapeutic target. Nucleic Acids Res. 2012;40:11\u201326.","journal-title":"Nucleic Acids Res"},{"key":"1515_CR37","doi-asserted-by":"publisher","first-page":"491","DOI":"10.3233\/JHD-130079","volume":"2","author":"W Liu","year":"2013","unstructured":"Liu W, Chaurette J, Pfister EL, Kennington LA, Chase KO, Bullock J, et al. Increased steady-state mutant huntingtin mRNA in Huntington\u2019s disease brain. J Huntingtons Dis. 2013;2:491\u2013500.","journal-title":"J Huntingtons Dis"},{"key":"1515_CR38","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1093\/hmg\/ddx033","volume":"26","author":"A Shin","year":"2017","unstructured":"Shin A, Shin B, Shin JW, Kim KH, Atwal RS, Hope JM, et al. Novel allele-specific quantification methods reveal no effects of adult onset CAG repeats on HTT mRNA and protein levels. Hum Mol Genet. 2017;26:1258\u201367.","journal-title":"Hum Mol Genet"},{"key":"1515_CR39","doi-asserted-by":"publisher","first-page":"R255","DOI":"10.1093\/hmg\/ddh227","volume":"13","author":"PR Buckland","year":"2004","unstructured":"Buckland PR. Allele-specific gene expression differences in humans. Hum Mol Genet. 2004;13:R255\u201360.","journal-title":"Hum Mol Genet"},{"key":"1515_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2164-14-571","volume":"14","author":"RM Smith","year":"2013","unstructured":"Smith RM, Webb A, Papp AC, Newman LC, Handelman SK, Suhy A, et al. Whole transcriptome RNA-Seq allelic expression in human brain. BMC Genom. 2013;14:1\u201315.","journal-title":"BMC Genom"},{"key":"1515_CR41","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/nn.4014","volume":"18","author":"K Becanovic","year":"2015","unstructured":"Becanovic K, N\u00f8rrem\u00f8lle A, Neal SJ, Kay C, Collins JA, Arenillas D, et al. A SNP in the HTT promoter alters NF-\u03baB binding and is a bidirectional genetic modifier of Huntington disease. Nat Neurosci. 2015;18:807\u201316.","journal-title":"Nat Neurosci"},{"key":"1515_CR42","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1073\/pnas.1221891110","volume":"110","author":"K Sathasivam","year":"2013","unstructured":"Sathasivam K, Neueder A, Gipson TA, Landles C, Benjamin AC, Bondulich MK, et al. Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease. Proc Natl Acad Sci U S A. 2013;110:2366\u201370.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1515_CR43","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1016\/j.celrep.2018.07.106","volume":"24","author":"MC Didiot","year":"2018","unstructured":"Didiot MC, Ferguson CM, Ly S, Coles AH, Smith AO, Bicknell AA, et al. Nuclear localization of huntingtin mRNA is specific to cells of neuronal origin. Cell Rep. 2018;24:2553\u20132560.e5.","journal-title":"Cell Rep"},{"key":"1515_CR44","doi-asserted-by":"publisher","first-page":"253","DOI":"10.3389\/fnmol.2017.00253","volume":"10","author":"WJ Szlachcic","year":"2017","unstructured":"Szlachcic WJ, Wiatr K, Trzeciak M, Figlerowicz M, Figiel M. The generation of mouse and human huntington disease iPS cells suitable for In vitro studies on huntingtin function. Front Mol Neurosci. 2017;10:253.","journal-title":"Front Mol Neurosci"},{"key":"1515_CR45","first-page":"1047","volume":"8","author":"WJ Szlachcic","year":"2015","unstructured":"Szlachcic WJ, Switonski PM, Krzyzosiak WJ, Figlerowicz M, Figiel M. Huntington disease iPSCs show early molecular changes in intracellular signaling, the expression of oxidative stress proteins and the p53 pathway. DMM Dis Model Mech. 2015;8:1047\u201357.","journal-title":"DMM Dis Model Mech"},{"key":"1515_CR46","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.neuron.2011.06.031","volume":"71","author":"S Saxena","year":"2011","unstructured":"Saxena S, Caroni P. Selective neuronal vulnerability in neurodegenerative diseases: from stressor thresholds to degeneration. Neuron. 2011;71:35\u201348.","journal-title":"Neuron"},{"key":"1515_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1101\/cshperspect.a024240","volume":"7","author":"M Jimenez-Sanchez","year":"2017","unstructured":"Jimenez-Sanchez M, Licitra F, Underwood BR, Rubinsztein DC. Huntington\u2019s disease: mechanisms of pathogenesis and therapeutic strategies. Cold Spring Harb Perspect Med. 2017;7:1\u201322.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"1515_CR48","doi-asserted-by":"publisher","first-page":"166699","DOI":"10.1016\/j.jmb.2020.10.033","volume":"432","author":"M Jazurek-Ciesiolka","year":"2020","unstructured":"Jazurek-Ciesiolka M, Ciesiolka A, Komur AA, Urbanek-Trzeciak MO, Krzyzosiak WJ, Fiszer A. RAN translation of the expanded CAG repeats in the SCA3 disease context. J Mol Biol. 2020;432:166699.","journal-title":"J Mol Biol"},{"key":"1515_CR49","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.neuron.2015.10.038","volume":"88","author":"M Ba\u00f1ez-Coronel","year":"2015","unstructured":"Ba\u00f1ez-Coronel M, Ayhan F, Tarabochia AD, Zu T, Perez BA, Tusi SK, et al. RAN translation in Huntington disease. Neuron. 2015;88:667\u201377.","journal-title":"Neuron"},{"key":"1515_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7554\/eLife.64564","volume":"10","author":"TS Onur","year":"2021","unstructured":"Onur TS, Laitman A, Zhao H, Keyho R, Kim H, Wang J, et al. Downregulation of glial genes involved in synaptic function mitigates Huntington\u2019s disease pathogenesis. Elife. 2021;10:1\u201330.","journal-title":"Elife"},{"key":"1515_CR51","doi-asserted-by":"publisher","first-page":"104963","DOI":"10.1016\/j.nbd.2020.104963","volume":"143","author":"DK Wilton","year":"2020","unstructured":"Wilton DK, Stevens B. The contribution of glial cells to Huntington\u2019s disease pathogenesis. Neurobiol Dis. 2020;143:104963.","journal-title":"Neurobiol Dis"},{"key":"1515_CR52","doi-asserted-by":"publisher","first-page":"107737","DOI":"10.1016\/j.biotechadv.2021.107737","volume":"49","author":"P Sledzinski","year":"2021","unstructured":"Sledzinski P, Dabrowska M, Nowaczyk M, Olejniczak M. Paving the way towards precise and safe CRISPR genome editing. Biotechnol Adv. 2021;49:107737.","journal-title":"Biotechnol Adv"},{"key":"1515_CR53","doi-asserted-by":"publisher","first-page":"8151","DOI":"10.1038\/s41598-020-65005-0","volume":"10","author":"N Minshall","year":"2020","unstructured":"Minshall N, Git A. Enzyme- and gene-specific biases in reverse transcription of RNA raise concerns for evaluating gene expression. Sci Rep. 2020;10:8151.","journal-title":"Sci Rep"},{"key":"1515_CR54","doi-asserted-by":"publisher","first-page":"22137","DOI":"10.1038\/s41598-020-78790-5","volume":"10","author":"V Fodale","year":"2020","unstructured":"Fodale V, Pintauro R, Daldin M, Altobelli R, Spiezia MC, Bisbocci M, et al. Analysis of mutant and total huntingtin expression in Huntington\u2019s disease murine models. Sci Rep. 2020;10:22137.","journal-title":"Sci Rep"},{"key":"1515_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/JHD-170235","volume":"6","author":"JP Liu","year":"2017","unstructured":"Liu JP, Zeitlin SO. Is huntingtin dispensable in the adult brain? J Huntington\u2019s Dis. 2017;6:1\u201317.","journal-title":"J Huntington\u2019s Dis"},{"key":"1515_CR56","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.neuron.2016.02.003","volume":"89","author":"F Saudou","year":"2016","unstructured":"Saudou F, Humbert S. The biology of huntingtin. Neuron. 2016;89:910\u201326.","journal-title":"Neuron"},{"key":"1515_CR57","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1056\/NEJMoa1900907","volume":"380","author":"SJ Tabrizi","year":"2019","unstructured":"Tabrizi SJ, Leavitt BR, Landwehrmeyer GB, Wild EJ, Saft C, Barker RA, et al. Targeting huntingtin expression in patients with Huntington\u2019s disease. N Engl J Med. 2019;380:2307\u201316.","journal-title":"N Engl J Med"},{"key":"1515_CR58","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/S1474-4422(17)30280-6","volume":"16","author":"EJ Wild","year":"2017","unstructured":"Wild EJ, Tabrizi SJ. Therapies targeting DNA and RNA in Huntington\u2019s disease. Lancet Neurol. 2017;16:837\u201347.","journal-title":"Lancet Neurol"},{"key":"1515_CR59","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1172\/JCI80743","volume":"125","author":"EJ Wild","year":"2015","unstructured":"Wild EJ, Boggio R, Langbehn D, Robertson N, Haider S, Miller JRC, et al. Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington\u2019s disease patients. J Clin Invest. 2015;125:1979\u201386.","journal-title":"J Clin Invest"},{"key":"1515_CR60","doi-asserted-by":"publisher","first-page":"e96854","DOI":"10.1371\/journal.pone.0096854","volume":"9","author":"D Macdonald","year":"2014","unstructured":"Macdonald D, Tessari MA, Boogaard I, Smith M, Pulli K, Szynol A, et al. Quantification assays for total and polyglutamine-expanded huntingtin proteins. PLoS One. 2014;9:e96854.","journal-title":"PLoS One."},{"key":"1515_CR61","doi-asserted-by":"publisher","first-page":"12166","DOI":"10.1038\/srep12166","volume":"5","author":"AL Southwell","year":"2015","unstructured":"Southwell AL, Smith SE, Davis TR, Caron NS, Villanueva EB, Xie Y, et al. Ultrasensitive measurement of huntingtin protein in cerebrospinal fluid demonstrates increase with Huntington disease stage and decrease following brain huntingtin suppression. Sci Rep. 2015;5:12166.","journal-title":"Sci Rep"},{"key":"1515_CR62","doi-asserted-by":"publisher","first-page":"7371","DOI":"10.1038\/s41598-018-25095-3","volume":"8","author":"J Corey-Bloom","year":"2018","unstructured":"Corey-Bloom J, Haque AS, Park S, Nathan AS, Baker RW, Thomas EA. Salivary levels of total huntingtin are elevated in Huntington\u2019s disease patients. Sci Rep. 2018;8:7371.","journal-title":"Sci Rep"},{"key":"1515_CR63","doi-asserted-by":"publisher","first-page":"105652","DOI":"10.1016\/j.nbd.2022.105652","volume":"166","author":"NS Caron","year":"2022","unstructured":"Caron NS, Banos R, Aly AE, Xie Y, Ko S, Potluri N, et al. Cerebrospinal fluid mutant huntingtin is a biomarker for huntingtin lowering in the striatum of Huntington disease mice. Neurobiol Dis. 2022;166:105652.","journal-title":"Neurobiol Dis"},{"key":"1515_CR64","doi-asserted-by":"publisher","first-page":"101796","DOI":"10.1016\/j.scr.2020.101796","volume":"45","author":"A Ciolak","year":"2020","unstructured":"Ciolak A, Krzyzosiak WJ, Kozlowska E, Fiszer A. Generation of human iPS cell line IBCHi002-A from spinocerebellar ataxia type 3\/Machado-Joseph disease patient\u2019s fibroblasts. Stem Cell Res. 2020;45:101796.","journal-title":"Stem Cell Res"},{"key":"1515_CR65","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.scr.2016.07.004","volume":"17","author":"SK Hansen","year":"2016","unstructured":"Hansen SK, Stummann TC, Borland H, Hasholt LF, T\u00fcmer Z, Nielsen JE, et al. Induced pluripotent stem cell - derived neurons for the study of spinocerebellar ataxia type 3. Stem Cell Res. 2016;17:306\u201317.","journal-title":"Stem Cell Res"},{"key":"1515_CR66","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/978-1-4939-7825-0_27","volume":"1780","author":"M Fjodorova","year":"2018","unstructured":"Fjodorova M, Li M. Robust induction of DARPP32-expressing GABAergic striatal neurons from human pluripotent stem cells. Huntington\u2019s Dis Methods Mol Biol. 2018;1780:585\u2013605.","journal-title":"Huntington\u2019s Dis Methods Mol Biol"},{"key":"1515_CR67","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1093\/clinchem\/hvaa125","volume":"66","author":"AS Whale","year":"2020","unstructured":"Whale AS, De Spiegelaere W, Trypsteen W, Nour AA, Bae Y-K, Benes V, et al. The Digital MIQE Guidelines Update: minimum information for publication of quantitative digital PCR experiments for 2020. Clin Chem. 2020;66:1012\u201329.","journal-title":"Clin Chem"}],"container-title":["BMC Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12915-023-01515-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12915-023-01515-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12915-023-01515-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,4]],"date-time":"2023-02-04T04:56:18Z","timestamp":1675486578000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcbiol.biomedcentral.com\/articles\/10.1186\/s12915-023-01515-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,1]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1515"],"URL":"https:\/\/doi.org\/10.1186\/s12915-023-01515-3","relation":{},"ISSN":["1741-7007"],"issn-type":[{"value":"1741-7007","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,1]]},"assertion":[{"value":"6 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed on animals were approved and monitored by the Local Ethical Commission for Animal Experiments in Poznan (Poland) (approval number 64\/2018).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17"}}